



## Review

The *cfr* and *cfr*-like multiple resistance genes

Birte Vester

Dept. of Biochemistry and Molecular Biology, University of Southern Denmark, Denmark



## ARTICLE INFO

## Article history:

Received 5 October 2017

Accepted 11 December 2017

Available online 2 March 2018

## Keywords:

Cfr

Cfr-like enzymes

Antibiotic resistance

RNA methylation

## ABSTRACT

The Cfr methyl transferase causes an RNA methylation of the bacterial ribosomes impeding reduced or abolished binding of many antibiotics acting at the peptidyl transferase center. It provides multi-resistance to eight classes of antibiotics, most of which are in clinical and veterinary use. The *cfr* gene is found in various bacteria in many geographical locations and placed on plasmids or associated with transposons. Cfr-related genes providing similar resistance have been identified in Bacillales, and now also in the pathogens *Clostridium difficile* and *Enterococcus faecium*. In addition, the presence of the *cfr* gene has been detected in harbours and food markets.

© 2018 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

## 1. Introduction

There is an increasing concern about pathogenic bacteria obtaining resistance to the antibiotics used for treatment of humans and animals. To address the problems with antibiotic resistance we need knowledge about the various resistance mechanisms, how they can be disseminated, which bacteria contain them and where they come from. Antibiotic resistance is not a new phenomenon, see e.g. review by [1]. There are many ways bacteria can obtain and exert antibiotic resistance and new resistance determinants are continuously discovered. The strategies bacteria use to evade the effects of antibiotics, can be grouped into three general mechanisms: increased antibiotic efflux out of the cell or reduced antibiotic influx into the cell, enzymatic inactivation of antibiotics through drug modification or cleavage, and the alteration of the antibiotic binding site. A bacterial cell contains many different target sites for antibiotics, but in general, an antibiotic interfere with or inhibits an essential cellular pathway or process. The most common antibiotic targets include bacterial cell wall synthesis; the bacterial membrane; the DNA replication machinery; RNA polymerase; the folate biosynthesis pathway; and the protein synthesis machinery.


The ribosome is a major site of antibiotic action in the bacterial cell and is targeted by a large and chemically diverse group of antibiotics. A number of these antibiotics have important applications in human and veterinary medicine in the treatment of bacterial infections. The antibiotic binding sites are clustered at functional

centers of the ribosome, such as the decoding center on the 30S subunit, the peptidyl transferase center (PTC), the GTPase center, and the peptide exit tunnel on the 50S subunit and the subunit interface in the 70S ribosome. The resistance mechanisms to antibiotics targeting the ribosomes include all three mechanism mentioned above. The alterations of the ribosomal antibiotic binding sites providing antibiotic resistance can be either mutation or methylation. While mutations appear spontaneously the gaining of methylations normally need a gene transfer of a methyl transferase gene. Since the 1950s, about 17 methyltransferases providing antibiotic resistance has been discovered, reviewed by [2,3]. One of the most recently discovered and most exceptional regarding nature of modification and mechanism of methylation is the Cfr methyltransferase [4–7] and Cfr and Cfr-like proteins have a potential to become a serious threat for antibiotic treatment. The sections below will present an overview of our current knowledge about Cfr and Cfr-like methyltransferases and especially cover aspects that have not previously been reviewed.

## 2. The Cfr methyltransferase and its target

The *cfr* gene codes for Cfr, a 349 amino acid long RNA methyltransferase, characterized as a radical SAM methyltransferase [8]. Cfr makes one methylation at the bacterial ribosome, causing reduced or abolished binding of many antibiotics that bind to the peptidyl transferase center (PTC) of the bacterial ribosomes [5] (Fig. 1A). Many different antibiotics act by binding to the ribosomes where their binding inhibits peptide synthesis and thereby bacterial growth [9]. Chemically different antibiotics can bind at the same specific sites in the ribosomes, although not totally

E-mail address: [b.vester@bmb.sdu.dk](mailto:b.vester@bmb.sdu.dk).



**Fig. 1.** The Cfr methylation site in the ribosome. **A:** A cut view of the *E. coli* ribosome with tRNA in P-site (purple) (PDB 4V9D) with a circle indicating the PTC where Cfr methylates A2503 23S RNA and thereby inhibits binding of the antibiotics at this region. **B:** central part of domain V 23S RNA constituting part of the PTC. The arrow points at position A2503 where Cfr adds a methyl group. **C:** the chemical structure of the double methylated A2503 with the enzymes shown in red. Cfr acts at the C-8 position and RlmN at the C-2 position. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

overlapping. The PTC is such a site and the Cfr enzyme methylates A2503 in 23S ribosomal RNA in the PTC (Fig. 1B and C). This is so far the only adenine nucleotide found to be methylated at the C-8 position [6] and this provides multi-resistance to eight different classes of antibiotics, most of which are in clinical and veterinary use. At its discovery on a plasmid in *Staphylococcus sciuri* [10] the gene was reported to provide resistance to chloramphenicol and florfenicol. A later study [11] showed that Cfr provided resistance to: Phenicols (including Chloramphenicol and Florfenicol), Lincosamides (including Clindamycin), Oxazolidinones (including Linezolid), Pleuromutilins (including Tiamulin and Valnemulin), and Streptogramin A's (including Pristinamycin II, Viginamycin M, and Dalfofpristin), all relevant for use in animals or humans. Since then, Cfr has also been shown to provide resistance to large macrolides [12], Hygromycin A and A201A [13].

### 3. Which bacteria contain the *cfr* resistance gene and where are they found

Until now, the *cfr* gene has mainly been identified in strains belonging to *Staphylococcus* but it has also been found in *Enterococcus*, *Bacillus*, *Proteus vulgaris*, *Escherichia coli*, *Macrococcus*

*caseolyticus*, *Jeotgalicoccus pinnipedialis*, and *Streptococcus suis* (reviewed in [14–17]). The *cfr* genes only contain small variations of a few amino acids as clearly seen by a BLAST search that shows 99% identity between Cfr's until the identity jumps to 77% and the following sequences must be characterised as Cfr-like proteins (see below). The *cfr* gene is often found on plasmids and if chromosomal it seems always associated with insertion elements. A detailed investigation detected a novel variant of the phenicol resistance transposon Tn558 in *Staphylococcus* isolates that harboured an additional resistance gene region, including the *cfr* gene, integrated into the *tnpC* reading frame [18]. They detected transcriptionally active forms of the IS21-558 element, known as minicircles, and suggest a pathway for mobility of the *cfr* gene. A more recent study analysed the genetic environment of the *cfr* gene in *Staphylococcus* isolates by sequencing of the up- and downstream regions on various plasmid types [19] and found insertion sequences (IS21-558, IS256, IS257, or IS1216E) as well as other resistance genes. In chromosomes they found the *cfr* gene to be bracketed by insertion sequences, such as IS256 or ISEnfa5 and stability tests confirmed that these *cfr*-containing regions could be looped out via IS-mediated recombination. Other examples can be found in [17,20–22] and references therein. A recent summary of the

structural variability in the regions surrounding the *cfr* gene on both plasmids or in the chromosomal DNA of various Gram-positive and Gram-negative bacteria is provided in [22]. It reveals twenty different contexts of the *cfr* gene and a considerable diversity and only three of these have no sign of insertion elements or transposition genes. Because of its presence on plasmids and with insertion elements the *cfr* gene is apparently easily disseminated. Spreading between genera is one aspect while geographical spreading is a different matter and the *cfr* gene is also found in many geographical locations. So far, the *cfr* gene is reported found in pathogenic bacteria in Belgium, Brazil, China, Columbia, Denmark, France, Germany, Ireland, Italy, Mexico, Spain, Thailand, and USA. In some cases its presence have been linked to treatment with linezolid e.g. [23]. This apparently global distribution probably picture where studies have looked for it, rather than its actual location. The presence of *cfr* on mobile genetic elements, and in all probability helped by heavily use of antibiotics in farming and disease treatment, suggests how it has been spread among bacteria. The ancestral origin of *cfr* genes has not been determined as is also the case for many other types of antibiotic resistance genes.

#### 4. *cfr* genes in the environment

From 2000 and up till now the *cfr* gene was looked for and found in bacterial strains from humans and animals, but in recent years there had been a few studies of the presence of *cfr* elsewhere and this is of interest for the dissemination of Cfr-mediated antibiotic resistance. Is it already everywhere or just in some specific environments, and caused by extensive antibiotic use? The first identification of the *cfr* gene was in Germany [10] and a recent study from Germany shed some light over the frequency and propagation of the *cfr* gene in staphylococci from nasal swabs [15]. They found *cfr* in 12 of 52 calves at three farms with a history of florfenicol use, no *cfr* in 10 humans living on these farms, no *cfr* in 142 calves at 16 farms in the same area not using florfenicol, *cfr* in 11 of 67 pigs from three of eight farms, *cfr* in 1 of 12 humans living on these farms, *cfr* in 4 of 169 veterinarians from all over Germany, and *cfr* in 3 of 263 persons in contact with veterinarians [15]. Whether or not these numbers are alarming might be a matter of personal opinion but it might suggest that we keep an eye on the development and consider whether florfenicol should be discouraged in areas where *cfr* has been found.

Many findings of *cfr* genes come from China, and mostly from animals. Even without having solid data but based on estimates it can be concluded that the consumption of antibiotics in China for animal therapy and growth promotion antibiotics is huge [24,25]. Some of this ends up in the environment and might further select for presence of drug resistant bacteria. Li et al. 2015 investigated waste water and soil from seven swine feedlots and found approx.  $7 \times 10^4$ – $1.3 \times 10^6$  copies of *cfr* genes/mL in the water and  $1.1 \times 10^5$ – $5 \times 10^5$ /g in the soil [26]. Zhao et al. 2016 investigated soil samples from six Chinese swine farms with a record of florfenicol usage to detect florfenicol resistance genes (FRGs). Quantitative PCR and metagenomic sequencing revealed a significantly higher relative abundance of FRGs in the soils adjacent to the three swine farms where florfenicol was heavily used compared with the other sites. They conclude that it appears that the amount of florfenicol used on swine farms promotes the prevalence and abundance of FRGs, including the linezolid resistance genes *cfr* and *optrA*, in adjacent soils [24]. In another study Zeng et al. 2014 [27] investigated meat samples from Chinese markets for presence of *cfr*. 118 pork and chicken samples from Guangzhou markets were screened by PCR and 22 *Staphylococcus* isolates obtained from 12 pork and 10 chicken samples harboured *cfr*. The 22 *cfr*-positive staphylococci isolates, included eight *Staphylococcus equorum*, seven

*Staphylococcus simulans*, four *Staphylococcus cohnii*, and three *S. sciuri*, and in 14 isolates, the *cfr* gene was found located on plasmids [27]. In a fourth study Wang et al. 2015 [28] studied the prevalence and genetics of *cfr* in *Staphylococcus* isolates recovered from pigs, workers, and meat-handling facilities (a slaughterhouse and a hog market). Twenty (4.5%) *cfr*-positive *Staphylococcus* isolates (18 *S. simulans*, 1 *S. cohnii*, and 1 *S. aureus*) were derived from: pigs (16/312), the environment (2/52), and workers (2/80). The authors conclude that both clonal spread and horizontal transmission via mobile elements contributed to the *cfr* dissemination among staphylococcal isolates obtained from different sources [28]. Although it is impossible to make safe conclusions for all China based on the above studies plus the findings of *cfr* in bacteria directly from humans and animals referred to previously, it points to a disturbing development.

In addition to the studies from Germany and China there is also a study of *cfr* in ballast and harbour waters in Singapore [29]. This study screened for 13 antibiotic resistant genes in six samples and found that *cfr* was present in 2.00–5.21 copies/mL. It also found a strong positive correlation between *cfr* and *Pseudomonas aeruginosa* gene copies, but so far *cfr* has not been found in *P. aeruginosa*. There is too little information to even speculate what these findings mean in terms of spreading of Cfr resistance, but hopefully the future will provide us with more information.

#### 5. Cfr-like methyltransferases

Usually genes and the proteins they code for share some homology with others and this can often give a hint to the evolution of the genes, from where they originate and their function. Cfr is a bit special in this aspect, at least based on the available sequence information. The  $m^8A$  made by Cfr is so far only found at the A2503 position in 23S ribosomal RNA (*E. coli* numbering) but not in other RNAs or at other positions. The same nucleotide is modified by RlmN that makes an  $m^2A$  methylation [30], see Fig. 1C. RlmN is a housekeeping enzyme apparently present in all bacteria and it is not a resistance determinant. Cfr and RlmN show some similarity (34% identity based on RlmN from *E. coli*) and both are so-called radical SAM methyltransferases but not closely related [31,32], although they use the same unique molecular mechanism for methylation [8]. Doing BLAST searches with the Cfr sequence results in various sequences, with some that are very obviously Cfr with small variations plus a huge number of sequences with less similarity to Cfr. Some of these are probably true Cfr-likes (in the sense that they make  $m^8A$  as Cfr do); some are RlmN or RlmN-like and some probably something else. Unfortunately, the automatic database annotation for these enzymes is not trustworthy and will not truly distinguish between Cfr-likes and RlmNs. This can be overcome by performing an alignment followed by a detailed analysis of a number of 13 differential conserved amino acids at specific positions [33] that are shown in Fig. 2B.

We have previously been searching for Cfr-likes, by which we mean enzymes that are significantly different from Cfr (>20% identity difference) but perform the same  $m^8A$ 2503 modification as Cfr. It is thus not sufficient to use gene sequence identity as the only criterion, it has to provide the modification and show the same antibiotic resistance profile as Cfr. In 2011 there were not that many sequences similar to Cfr in the databases but we examined some *cfr*-like genes from non-pathogenic Bacillales (*Bacillus amyloliquefaciens*, *Bacillus clausii*, *Brevibacillus brevis*), which provided the same multi-drug resistance as Cfr when transferred to *E. coli* [34]. Later we also showed the same for a *cfr*-like gene from *Paenibacillus* sp. Y412MC10 [33]. Their similarity to Cfr is shown in Fig. 2 and in Table 1. They can thus provide antibiotic resistance to *E. coli* but they have not been found in pathogenic strains and whether these

## A

```

Cfr      MNFNNTKY GKIQEFLRSN NEPDYRIKQI TNAIFKQIS RFEDMKVLPK LLREDLINNF GETVLNIKLL AEQNSEQVTK
Cfr (B)  MQQKNKY IRIQEFLKQN KFPNYRMKQI TNAIFPGRIN NFNEITVLPK SLRDMLIEEF GESILNIVPL KAQQSTQVSK
BacMulti MKVNVNATKY ERLKHLNAL NEPTYRYKQI TEAIFKHRIQ AFNKMTLPK ALRESLINEF GPSILTVEVP LETTSQVTK
Paenibac MKYLSKY EKIRKILSAL NQPNYRYSQI TEAIFKNKIG NFEAMNNLPK PVRNELIKEL GNNVLSITPK MEQKSNQVSK
Brevibac MKLTSKY ETIRRILSEC KQPEYRYAQI MDAIFKQIG EYERMILPK FLRDELNRIL GPNVCSIAVP KELTSKQVSK
Cfr (C)  MSKY KMKQLIADM RLPEYRYQQL LDAVFLOQIM RFEDMKLPLK TLREKLVEQF GETVVEIKAI HHEKSMQTDK
Consensus .....SKY .k.k..l... ..P.YRYkQi t#A!Fkq.I. .%#.m..LPK .lR#.Li..f Ge.!!..p. .e..S.Qv.K
81
VLFVSKNER VETVNMKYKA GWESFCISSQ CGCNFGCKFC ATGDIGLKKN LTVDEITDQV LYFHLGHQI DSISFMGMGE ALANRQVFDA
VLFGISGDEK IETVNMKYKA GWESFCISSQ CGCNFGCKFC ATGDIGLKRN LTVDEITDQI LYFHLQGHSI DSISFMGMGE ALANVQVFDA
VLLKVGAGNQ VEAVRMHYEA GWESFCISSQ CGCGLGCTFC STGAIGLKQN LSADEMTDQL LYFYLKGHSL DSVSFMGMGE ALANVRIFDA
ILFAIPGDEY IESVRLSYQT GWESYCISSQ CGCGFGCTFC ATGTGLGKRN LTVDEITDQL LYFPLNHHPL DSVSFMGMGE ALANPYVFDA
VLFPAIPGDEQ VEAVRLTYER GWKSYCISTQ CGCGFRCKFC ATGTIGLKRN LTADEITDQL LYFRLNGHSL DSISFMGMGE ALANPHIFEA
VLPFLSDGNR VETVGLFYKE GWNSFCISSQ SCGCGFKCFC ATGTGLGKRN LTVDEITDQI LYFMQQGCSI NSISFMGMGE PFANPQVFEA
!Lf..sg.#. !EtV.$.Yk. GwEs%CISSQ cGcGfgCkfc atGtiGLkrN Lt.DEiTDQ. LYF.l.ghs #S!SFMGMGE alanpq!F#A
171
LDSFTDPNLF ALSPRRLSIS TIGIIPSICK ITQEYPQVNL TFSLSHPYSE ERSKLPIND RYPIDEVMI LDEHIRLTSR KVIYIAYIMLP
LNVLTDPALF ALSPRRLSIS TIGIIPNIKK LTQNYQVNL TFSLSHPFNE QRSELMPIE RYPLSDVMDT LDEHIRVTSR KVIYIAYIMLH
LNVLVDRLQF ALSPRRITVS TVGIIPNIQR MTSSFPQMN L TFSLSHPFHD QRSELMPINN KYPLDQVMNV LDQHIHETGR KVIYIAYIMLR
LHLLTDPKLF GLGHRRTIVS TIGLLPGVKK LTKEFPQINL TFSLSHPFHD QRSELMPINN HFPLEVMTV LDEHIQQTGR KVIYIAYILLR
MTILTDPYLF GLGHRRTIVS TIGLLPGIDK LTREFPQVNL TFSLSHPFDD QRSELMPIE RFPVRDVIA LDRHIRETGR KVIYIAYILLR
LHDLTAPELF GLSQRRTIVS TIGIVPGIQK LTREYPQVNL AYSLHAPTDR LRETLMPITK TYPLGQVLDL LDQHIRQTNR KVFAYIAYIMLK
$.ltdp.LF gLs.RRit!S T!Gi.Pg!qk lT.e%PQvNL t%SLHsPf. qRseLMPin. .%Pl.#V$. LDqHir.T.R KV%iAY!$L.
261
GVNDSLEHAN EVVSLKSRV KSGKLYHVN L IRYNPTISAP EMYGEANEQ VEAIFYKVLKS AGIHVTIRSQ FGIDIDAACG QLYGNYQ+3
GVNDSIEHAK EVVNLRLGRY RSGNLYHVN I IRYNPTVSSR MRFEANEKC LVNFYKLLKS AGIKVTIRSQ FGIDIDAACG QLYGNYQ+5
GVNDSSEKHA EALVKRILNN- RYPHLYHVN I IRYNPTVGT ENYGTIEEK LQTFYRVVKS ARIPTVIRSQ FGREIDAACG QLYGNYQ+4
GINDSTKHA AVADLLRERG SWEHLYHVN L IPYNSTDATS QSFVESDQNS INMFLRILKS KGIHVTVRTQ FGSIDINAACG QLYGSNG+2
GVNDSTHAE AVAELLRGRG AWEHLYHVN L IPFNSTEVTP DSYRQSDPSR IKAFVRLKS RGSVTVRTQ FGSIDINAACG QLYRSE
dVNSDRHAE QLTKLLFKHK KYPLLYHLDL IPYNQTVT- ETMVPSSHR IKAFCRIHN AGISVNIRTQ FGSIDINAACG QLAGAYR+76
g!NDS..Hae .l.kll.... .y..LYHv#l Ip%N.T..t. e.....s..... i.af.ri.ks agI.vt!rtQ FGs#i#AACG QLyg.y....

```

## B

```

1
Cfr      MNF NNTKYGKIQ EFLRSNNEPD YRIKQITNAI FKQIRSFED MKVLPKLLRE
RlmN    MSEQLVTPEN VTTKDGKINL LDLNRQ-QMR EFKDLGKEP FRADQVMKWM YHYCCDNFDE MTDINKVLRG
70
DLINNFGETV LNIKLLAEQN SEQVTKVLFV VSKNERVETV NMKYKAGWES FCISSQCGCN FGCKFCATGD IGLKKNLTVD
KLKEV--AEI RAPEVVEEQR SSDGTIKWAI AVGDQRVETV YIP-EDDRAT LCVSSQVGA LECKFCSTAQ QGFNRNLRSV
150
EITDQVLYFH LL----- GHQIDSISFM GMGEALAN-R QVFDALDSFT DPNFLFALSPR RLSISTIGII PSIKKITQEY
EIIGQVWRAA KIVGAAKVTG QRPITNVMM GMGPELLNLN NVVPAMEIML DDFGFLSKR RVTLSTSGVV PALDKLG-DM
230
PQVNLTFSLH SPYSEERSKL MPINDRYPID EVMNILDEHI RLTSR---KV YIAYIMLPGV NDSLEHANEV VSLKSRYSK
IDVALAISLH APNDEIRDEI VPINKKYNIE TFLAAVRRYL EKSANQGV TIEYVLDHV NDGTEHAHQ AELLKDPCK
310
GKLYHVNLR YNPTISAPEM YGEANEQVE AFYKVLKSAG IHVTIRSQFG IDIDAACGQL YGNYQNSQ
-----INLIP WNFPPGAP-- YGRSSNSRID RFSKVLMSYG FTTIVRKTFRG DDIDAACGQL AGDVIDRTRK TLRKRMQGEA
IDIKAV

```

**Fig. 2.** A. Sequence alignment of Cfr and Cfr-like enzymes to highlight similarities and differences. Red shows amino acids that are >90% conserved in the aligned sequences, blue >50% conserved and black less conserved. The alignment is made using <http://multalin.toulouse.inra.fr/multalin/> and the following sequences: Cfr - WP 001010505.1, Cfr(B) - WP002349981.1 that includes Cfr-like from *Clostridium difficile* and *Enterococcus faecium*, BacMulti - WP 011245929 that includes Cfr-like ClBc from *Bacillus clausii*, Paenibac - WP 015735625 that includes Cfr-like ClPa from *Paenibacillus* sp. Y412MC10, Brevibac - WP 015892743 that includes Cfr-like ClBb from *Brevibacillus brevis*, and Cfr(C) - WP002578771.1 that includes Cfr-like from *Campylobacter* and *Clostridium difficile*. Cfr-like ClBa from *Bacillus amyloliquefaciens* are <20% different from Cfr(B) and can thus be characterised as a Cfr(B) like. B. Sequence alignment of Cfr and RlmN (WP 000003317.1) enzymes showing the 13 positions (grey marking) that can be used to discriminate between these two similar enzymes making m<sup>8</sup>A or m<sup>2</sup>A respectively. The amino acids marked with grey are selectively conserved in a designated Cfr and RlmN alignment with multiple sequences [33], meaning that 70% have a specific amino acid in all Cfrs and another specific amino acid in RlmNs. The one aa displacement at 94 in RlmN and the identical M at 286 are because this representation are based on only two sequences. Underlining indicate the CxxxCxxC motif cysteines involved in binding of a Fe-S cluster and a characteristic of radical SAM enzymes. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

should be called antibiotic resistance genes is a matter of definition as discussed in [35]. These cfr-like genes are found on the chromosomes but no studies of their genetic context have been reported. Recently, a Cfr-like orthologue was also found in *Paenibacillus* sp. LC231 from an isolated ecosystem and with 95% identity to the *Paenibacillus* sp. Y412MC10 Cfr-like enzyme [36]. This is in accordance with the general view that genes providing protection to antibiotics have always been around and will always be present in the bacterial population, see e.g. [1,37].

Recently, Cfr-like methyltransferases have also been verified in pathogenic strains and a new naming for these genes has started (<http://faculty.washington.edu/marilynr/>). To avoid genes with multiple names and to be able to identify the presence of very similar genes they get single letter alphabetic extensions if >20% identity difference. At present we have Cfr(B) in *Clostridium difficile*/*Peptoclostridium difficile* [38,39] and in *Enterococcus faecium* [40,41] and Cfr(C) in *Campylobacter* [42] and in *C. difficile* and *Clostridium bolteae* [43]. Cfr(B) and Cfr(C) are also included in the alignment

**Table 1**

% Similarity, as obtained from BLAST searches at NCBI <https://blast.ncbi.nlm.nih.gov/Blast.cgi>, between all sequences aligned in Fig. 2 and supplemented by comparisons with RlmN. All sequences are >20% different from each other as well as >20% different from Cfr.

% Identity	cfr	cfr(B)	BacMulti	Paenibac	Brevibac	Cfr(C)
Cfr(B)	75	—	—	—	—	—
BacMulti	62	63	—	—	—	—
Paenibac	57	60	59	—	—	—
Brevibac	57	59	59	72	—	—
Cfr(C)	56	52	48	52	56	—
RlmN	34	32	32	31	34	34

Fig. 2 and in Table 1 together with their % similarity. It is expected that more examples in pathogenic strains will appear in the future reinforcing the current concern about Cfr and Cfr-like proteins. Also, there are indications that these cfr-like genes may have been inserted into the chromosomes via transposons [40] [41] or other insertion mechanisms and thus also have the possibility to easily spread further.

## 6. Future perspectives

The threat of antibiotic resistance to our ability to treat bacterial diseases is truly worrisome but the impacts of the various resistance determinants are difficult to predict. We cannot eradicate antibiotic resistance but only try to minimize selection for resistance and spreading of resistant strains. Cfr and Cfr-like enzymes cause multiple antibiotic resistances to drugs binding at PTC – meaning that selection for the presence of this gene can probably be due to any of these drugs. Thus, one problem with Cfr and Cfr-like resistance is that many different antibiotics can select for its uptake or persistence and that the resistance mechanism functions in many bacterial strains. Also, it is well tolerated and cause very little fitness cost [44]. Nonetheless, our knowledge in the field is still too limited and important questions emerge: How widespread are *cfr* and the *cfr*-like genes? Are the Cfr-like enzymes as effective as the original Cfr in providing antibiotic resistance? Is m<sup>8</sup>A2503 methylation their primary function, or do they also do something else not related to antibiotic resistance?

## Conflict of interest

No conflict of interest.

## Acknowledgement

Thanks to Claus Asger Lykkebo for help with Fig. 1 and Clare Kirkpatrick for comments on the manuscript.

## References

- [1] Davies J, Davies D. Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev* 2010;74:417–33.
- [2] Vester B, Long KS. Antibiotic resistance in bacteria caused by modified nucleotides in 23S ribosomal RNA. In: Grosjean H, editor. DNA and RNA modification enzymes: structure, mechanism, function and evolution, *landes bioscience*; 2009. p. 540–52.
- [3] Conn GL, Savic M, Macmaster R. Antibiotic resistance in bacteria through modification of nucleosides in 16S ribosomal RNA. In: Grosjean H, editor. DNA and RNA modification enzymes: structure, mechanism, function and evolution, *landes bioscience*; 2009. p. 524–36.
- [4] Boal AK, Grove TL, McLaughlin MI, Yennawar NH, Booker SJ, Rosenzweig AC. Structural basis for methyl transfer by a radical SAM enzyme. *Science* 2011;332:1089–92.
- [5] Kehrenberg C, Schwarz S, Jacobsen L, Hansen LH, Vester B. A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503. *Mol Microbiol* 2005;57:1064–73.
- [6] Giessing AM, Jensen SS, Rasmussen A, Hansen LH, Gondela A, Long K, et al. Identification of 8-methyladenosine as the modification catalyzed by the radical SAM methyltransferase Cfr that confers antibiotic resistance in bacteria. *RNA* 2009;15:327–36.
- [7] Grove TL, Livada J, Schwalm EL, Green MT, Booker SJ, Silakov A. A substrate radical intermediate in catalysis by the antibiotic resistance protein Cfr. *Nat Chem Biol* 2013;9:422–7.
- [8] Grove TL, Benner JS, Radle MI, Ahlum JH, Landgraf BJ, Krebs C, et al. A radically different mechanism for S-adenosylmethionine-dependent methyltransferases. *Science* 2011;332:604–7.
- [9] Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. *Nat Rev Microbiol* 2014;12:35–48.
- [10] Schwarz S, Werckenthin C, Kehrenberg C. Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in *Staphylococcus sciuri*. *Antimicrob Agents Chemother* 2000;44:2530–3.
- [11] Long KS, Poehlsgaard J, Kehrenberg C, Schwarz S, Vester B. The cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. *Antimicrob Agents Chemother* 2006;50:2500–5.
- [12] Smith LK, Mankin AS. Transcriptional and translational control of the *mfr* operon, which confers resistance to seven classes of protein synthesis inhibitors. *Antimicrob Agents Chemother* 2008;52:1703–12.
- [13] Polikanov YS, Starosta AL, Juetz MF, Altman RB, Terry DS, Lu W, et al. Distinct tRNA accommodation intermediates observed on the ribosome with the antibiotics hygromycin A and A201A. *Mol Cell* 2015;58:832–44.
- [14] Bender J, Strommenger B, Steglich M, Zimmermann O, Fenner I, Lensing C, et al. Linezolid resistance in clinical isolates of *Staphylococcus epidermidis* from German hospitals and characterization of two cfr-carrying plasmids. *J Antimicrob Chemother* 2015;70:1630–8.
- [15] Cuny C, Arnold P, Hermes J, Eckmanns T, Mehrj J, Schoenfelder S, et al. Occurrence of cfr-mediated multiresistance in staphylococci from veal calves and pigs, from humans at the corresponding farms, and from veterinarians and their family members. *Vet Microbiol* 2017;200:88–94.
- [16] Long KS, Vester B. Resistance to linezolid caused by modifications at its binding site on the ribosome. *Antimicrob Agents Chemother* 2012;56:603–12.
- [17] Liu XQ, Wang J, Li W, Zhao LQ, Lu Y, Liu JH, et al. Distribution of cfr in *Staphylococcus* spp. and *Escherichia coli* strains from pig farms in China and characterization of a novel cfr-carrying F43:A-B- plasmid. *Front Microbiol* 2017;8:329.
- [18] Kehrenberg C, Aarestrup FM, Schwarz S. IS21-558 insertion sequences are involved in the mobility of the multiresistance gene *cfr*. *Antimicrob Agents Chemother* 2007;51:483–7.
- [19] He T, Wang Y, Schwarz S, Zhao Q, Shen J, Wu C. Genetic environment of the multi-resistance gene *cfr* in methicillin-resistant coagulase-negative staphylococci from chickens, ducks, and pigs in China. *Int J Med Microbiol* 2014;304:257–61.
- [20] Michael GB, Freitag C, Wendlandt S, Eidam C, Fessler AT, Lopes GV, et al. Emerging issues in antimicrobial resistance of bacteria from food-producing animals. *Future Microbiol* 2015;10:427–43.
- [21] Shen JZ, Wang Y, Schwarz S. Presence and dissemination of the multi-resistance gene *cfr* in Gram-positive and Gram-negative bacteria. *J Antimicrob Chemother* 2013;68:1697–706.
- [22] Schwarz S, Shen J, Kadlec K, Wang Y, Brenner Michael G, Fessler AT, et al. Lincosamides, streptogramins, phenicols, and pleuromutilins: mode of action and mechanisms of resistance. *Cold Spring Harb Perspect Med* 2016;6.
- [23] Yang XJ, Chen Y, Yang Q, Qu TT, Liu LL, Wang HP, et al. Emergence of cfr-harboring coagulase-negative staphylococci among patients receiving linezolid therapy in two hospitals in China. *J Med Microbiol* 2013;62:845–50.
- [24] Zhao Q, Wang Y, Wang S, Wang Z, Du XD, Jiang H, et al. Prevalence and abundance of florfenicol and linezolid resistance genes in soils adjacent to swine feedlots. *Sci Rep* 2016;6. 32192.
- [25] Krishnasamy V, Otte J, Silbergeld E. Antimicrobial use in Chinese swine and broiler poultry production. *Antimicrob Resist Infect Contr* 2015;4.
- [26] Li J, Shao B, Shen J, Wang S, Wu Y. Occurrence of chloramphenicol-resistance genes as environmental pollutants from swine feedlots. *Environ Sci Technol* 2013;47:2892–7.
- [27] Zeng ZL, Wei HK, Wang J, Lin DC, Liu XQ, Liu JH. High prevalence of Cfr-producing *Staphylococcus* species in retail meat in Guangzhou, China. *BMC Microbiol* 2014;14.
- [28] Wang J, Lin DC, Guo XM, Wei HK, Liu XQ, Chen XJ, et al. Distribution of the multidrug resistance gene *cfr* in *Staphylococcus* isolates from pigs, workers, and the environment of a hog market and a slaughterhouse in Guangzhou, China. *Foodb Pathog Dis* 2015;12:598–605.
- [29] Ng C, Le TH, Goh SG, Liang L, Kim Y, Rose JB, et al. A comparison of microbial water quality and diversity for ballast and tropical harbor waters. *PLoS One* 2015;10. e0143123.
- [30] Toh SM, Xiong L, Bae T, Mankin AS. The methyltransferase YfgB/RlmN is responsible for modification of adenosine 2503 in 23S rRNA. *RNA* 2008;14:98–106.
- [31] Ntokou E, Hansen LH, Kongsted J, Vester B. Biochemical and computational analysis of the substrate specificities of cfr and RlmN methyltransferases. *PLoS One* 2015;10. e0145655.

- [32] Stojkovic V, Noda-Garcia L, Tawfik DS, Fujimori DG. Antibiotic resistance evolved via inactivation of a ribosomal RNA methylating enzyme. *Nucleic Acids Res* 2016;44:8897–907.
- [33] Atkinson GC, Hansen LH, Tenson T, Rasmussen A, Kirpekar F, Vester B. Distinction between the cfr methyltransferase conferring antibiotic resistance and the housekeeping RlmN methyltransferase. *Antimicrob Agents Chemother* 2013;57:4019–26.
- [34] Hansen LH, Planellas MH, Long KS, Vester B. The order Bacillales hosts functional homologs of the worrisome cfr antibiotic resistance gene. *Antimicrob Agents Chemother* 2012;56:3563–7.
- [35] Martinez JL, Coque TM, Baquero F. What is a resistance gene? Ranking risk in resistomes. *Nat Rev Microbiol* 2015;13:116–23.
- [36] Pawlowski AC, Wang W, Koteva K, Barton HA, McArthur AG, Wright GD. A diverse intrinsic antibiotic resistome from a cave bacterium. *Nat Commun* 2016;7:13803.
- [37] Waglechner N, Wright GD. Antibiotic resistance: it's bad, but why isn't it worse? *BMC Biol* 2017;15:84.
- [38] Marin M, Martin A, Alcalá L, Cercenado E, Iglesias C, Reigadas E, et al. *Clostridium difficile* isolates with high linezolid MICs harbor the multiresistance gene *cfr*. *Antimicrob Agents Chemother* 2015;59:586–9.
- [39] Hansen LH, Vester B. A cfr-like gene from *Clostridium difficile* confers multiple antibiotic resistance by the same mechanism as the *cfr* gene. *Antimicrob Agents Chemother* 2015;59:5841–3.
- [40] Deshpande LM, Ashcraft DS, Kahn HP, Pankey G, Jones RN, Farrell DJ, et al. Detection of a new cfr-like gene, *cfr(B)*, in *Enterococcus faecium* isolates recovered from human specimens in the United States as part of the SENTRY antimicrobial surveillance program. *Antimicrob Agents Chemother* 2015;59:6256–61.
- [41] Bender JK, Fleige C, Klare I, Fiedler S, Mischnik A, Mutters NT, et al. Detection of a *cfr(B)* variant in German *Enterococcus faecium* clinical isolates recovered and the impact on linezolid resistance in *Enterococcus spp.* *PLoS One* 2016;11:e0167042.
- [42] Tang Y, Dai L, Sahin O, Wu Z, Liu M, Zhang Q. Emergence of a plasmid-borne multidrug resistance gene *cfr(C)* in foodborne pathogen *Campylobacter*. *J Antimicrob Chemother* 2017;72:1581–8.
- [43] Candela T, Marvaud JC, Nguyen TK, Lambert T. Acfr-like gene cfr(C) conferring linezolid resistance is common in *Clostridium difficile*. *Int J Antimicrob Agents* 2017 Sep;50(3):496–500. <https://doi.org/10.1016/j.ijantimicag.2017.03.013>.
- [44] LaMarre JM, Locke JB, Shaw KJ, Mankin AS. Low fitness cost of the multidrug resistance gene *cfr*. *Antimicrob Agents Chemother* 2011;55:3714–9.